Report: Studying Proteins Is a 5 Billion-Dollar Business
NEW YORK, Sept. 25, 2014 /PRNewswire/ -- The market for "proteomics" instruments, reagents and testing for research and diagnostic applications topped 5 billion dollars in 2013, and should see rapid revenue growth, according to Kalorama information. The healthcare market research publisher said demand for better understanding of proteins and a desire for new therapies is expected to continue to grow the proteomics market rapidly, despite cost pressures generally in research. The finding was made in Kalorama's latest report, Proteomics Markets for Research and IVD Applications.
The report can be obtained at: http://www.kaloramainformation.com/redirect.asp?progid=86681&productid=8359865.
Proteomics is the study of proteins, including the study of the structure and function of proteins. This includes the study of which proteins are expressed, when and where they are expressed, structure of proteins, roles of proteins, and interactions of proteins. In the Human Genome Project, researchers identified and mapped over 20,000 genes in the human genome. However, the proteins encoded by these genes were not all identified and characterized. Kalorama notes that this is an enormous undertaking. While the genome (sequence of nucleotides that make up an organism's genetic material) does not change, the proteome does change as based on various factors including factors that affect which genes are expressed.
"It's enormously difficult to study proteins, but hard-fought discoveries made in the research enable biomarker discovery, drug discovery, new IVDs and personalized solutions," said Bruce Carlson, Publisher of Kalorama Information. "There are many manufacturers willing to assist customers with technologies, creating a vibrant market."
Many different types of technologies are being used to study proteins, although the three technological pillars of the Human Proteome Project are mass spectrometry, antibodies (or antibody capture), and knowledge bases. Kalorama is bullish on future markets for these technologies.
The report says proteomics will remain a very active area of research for several years, and the knowledge derived from this research is expected to produce advances in the diagnosis and treatment of diseases. In addition, technology advances in proteomics will continue to gradually move into the clinical laboratory. This will include advances in technologies for detection and identification of proteins, and also the use of novel biomarkers in diagnostic assays.
"New platforms based on a wide range of proteomics technologies have already started to reach the in vitro diagnostics market," said Carlson. "The major question today is not whether or not these novel platforms and biomarkers will emerge as a significant market opportunity in the IVD market, but when. How long will it take for companies to obtain the required regulatory approvals? How long will it take for the tests to penetrate these markets? The answers to this question will vary with individual platforms and assays, and will depend on factors such as the unmet need, how well the new platform and assays meet that need, costs, etc."
Kalorama's report Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics. Find this report in addition to other industry leading research from Kalorama at: http://www.kaloramainformation.com/.
About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Photo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article